The new therapeutic concept of using a rho kinase inhibitor for the treatment of corneal endothelial dysfunction

Cornea

Volumn 30, Issue 10 SUPPL. 1, 2011, Pages

  Okumura, Naoki ^a,b   Koizumi, Noriko ^b   Ueno, Morio ^a   Sakamoto, Yuji ^b   Takahashi, Hiroaki ^b   Hamuro, Junji ^a   Kinoshita, Shigeru ^a,b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b DOSHISHA UNIVERSITY   (Japan)

Author keywords

corneal endothelial cells; Rho kinase; ROCK inhibitor; wound healing

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE;

CONFERENCE PAPER; CORNEAL ENDOTHELIAL CELL LOSS; HUMAN; PRIORITY JOURNAL; WOUND HEALING;

ANIMALS; CELL PROLIFERATION; CORNEAL DISEASES; ENDOTHELIUM, CORNEAL; MACACA FASCICULARIS; MODELS, ANIMAL; OPHTHALMIC SOLUTIONS; PROTEIN KINASE INHIBITORS; RABBITS; RHO-ASSOCIATED KINASES; WOUND HEALING;

EID: 80052758142     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3182281ee1     Document Type: Conference Paper

References (14)

1. Darlington JK, Adrean SD, Schwab IR. Trends of penetrating keratoplasty in the United States from 1980 to 2004. Ophthalmology. 2006;113:2171-2175. (Pubitemid 44848370)
2. Ishino Y, Sano Y, Nakamura T, et al. Amniotic membrane as a carrier for cultivated human corneal endothelial cell transplantation. Invest Ophthalmol Vis Sci. 2004;45:800-806. (Pubitemid 38868373)
3. Mimura T, Yamagami S, Yokoo S, et al. Cultured human corneal endothelial cell transplantation with a collagen sheet in a rabbit model. Invest Ophthalmol Vis Sci. 2004;45:2992-2997. (Pubitemid 39121827)
4. Mimura T, Yamagami S, Yokoo S, et al. Sphere therapy for corneal endothelium deficiency in a rabbit model. Invest Ophthalmol Vis Sci. 2005;46:3128-3135. (Pubitemid 44264297)
5. Koizumi N, Sakamoto Y, Okumura N, et al. Cultivated corneal endothelial cell sheet transplantation in a primate model. Invest Ophthalmol Vis Sci. 2007;48:4519-4526. (Pubitemid 351260967)
6. Koizumi N, Sakamoto Y, Okumura N, et al. Cultivated corneal endothelial transplantation in a primate: possible future clinical application in corneal endothelial regenerative medicine. Cornea. 2008;27(suppl 1):S48-S55.
7. Sumide T, Nishida K, Yamato M, et al. Functional human corneal endothelial cell sheets harvested from temperature-responsive culture surfaces. FASEB J. 2006;20:392-394. (Pubitemid 46671182)
8. Okumura N, Ueno M, Koizumi N, et al. Enhancement on primate corneal endothelial cell survival in vitro by a ROCK inhibitor. Invest Ophthalmol Vis Sci. 2009;50:3680-3687.
9. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science. 1995;269:1270-1272.
10. Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol. 2008;20:242-248.
11. Narumiya S, Ishizaki T, Uehata M. Use and properties of ROCK-specific inhibitor Y-27632. Methods Enzymol. 2000;325:273-284.
12. Coleman ML, Olson MF. Rho GTPase signalling pathways in the morphological changes associated with apoptosis. Cell Death Differ. 2002;9:493-504. (Pubitemid 34521177)
13. Okumura N, Koizumi N, Ueno M, et al. Enhancement of corneal endothelium wound healing by Rho-associated kinase (ROCK) inhibitor eye drops. Br J Ophthalmol. 2011;95:1006-1009.
14. Ishizaki T, Uehata M, Tamechika I, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000;57:976-983. (Pubitemid 30253382)